abametapir
Trade name: Xeglyze
Approved
Jul 24, 2020
Clinical trial activity
9 trials · 8 clinical orgs · 3 marketing orgs
Earliest trial started Apr 1, 2011 (NCT01336647)
Timeline
2010s
- Jan 1, 2011
Hatchtech Pty Ltd — Earliest Phase 2 Sponsor(trial)
- Jan 1, 2012
Hatchtech Pty Ltd — Earliest Phase 1 Sponsor(trial)
- Jan 1, 2014
Hatchtech Pty Ltd — Earliest Phase 3 Sponsor(trial)
2020s
- Jul 24, 2020
Hatchtech Pty Ltd — Earliest FDA Approval
- Jul 24, 2020
Dr. Reddy's Laboratories — Marketing Organization
- Jul 24, 2020
Hatchtech Pty Ltd — Marketing Organization
- Jul 24, 2020
Hatchtech Pty Ltd — NDA Secondary Org
- Jul 24, 2020
Hatchtech Pty Ltd — NDA Organization
- Jul 24, 2020
Ligand Pharmaceuticals — Marketing Organization
Indications
Approved for
Mechanism of action
- MetalloproteinaseINHIBITOR
Metalloproteinase inhibitor
Metalloproteases are essential for egg hatching. Abametapir chelates metal ions required for metalloprotease activity and inhibits metalloproteases.
- ZincSEQUESTERING AGENT
Zinc sequestering agent
Metalloproteases are essential for egg hatching. Abametapir chelates metal ions required for metalloprotease activity and inhibits metalloproteases.
- CopperSEQUESTERING AGENT
Copper sequestering agent
Metalloproteases are essential for egg hatching. Abametapir chelates metal ions required for metalloprotease activity and inhibits metalloproteases.
- IronSEQUESTERING AGENT
Iron sequestering agent
Metalloproteases are essential for egg hatching. Abametapir chelates metal ions required for metalloprotease activity and inhibits metalloproteases.
- N-sulphoglucosamine sulphohydrolaseANTAGONIST
SGSH antagonist
Approval history
- approvedJul 24, 2020
Chemistry & pharmacology
SMILES
Cc1ccc(-c2ccc(C)cn2)nc1- Mol. weight
- 184.24 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Discontinued
Oral
No
Parenteral
No
Topical
Yes
Sources
- ChEMBLCHEMBL2205807 ↗
Also known as
- abametapir
- abametapir
- abametapir
- abametapir
- ha44
- ha44
- ha44
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02097485 | Phase 2 | May 1, 2014 | Hatchtech Pty Ltd |
| NCT02060903 | Phase 3 | Feb 1, 2014 | Accelovance, Hatchtech Pty Ltd, INC Research |
| NCT02062060 | Phase 3 | Feb 1, 2014 | Accelovance, Hatchtech Pty Ltd, INC Research |
| NCT02061813 | Phase 1 | Jan 1, 2014 | Hatchtech Pty Ltd, TKL Research |
| NCT02062073 | Phase 1 | Jan 1, 2014 | Accelovance, Hatchtech Pty Ltd, TKL Research |
| NCT02010333 | Phase 2 | Apr 1, 2013 | Hatchtech Pty Ltd |
| NCT01907490 | Phase 2 | Mar 1, 2013 | Accelovance, Hatchtech Pty Ltd, Target Health Inc. |
| NCT01518699 | Phase 1 | Jan 1, 2012 | Hatchtech Pty Ltd, Spaulding Clinical Research Inc. |
| NCT01336647 | Phase 2 | Apr 1, 2011 | AXIS Clinicals Limited, Hatchtech Pty Ltd, Universal BioPharma Research Inc. |
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hatchtech Pty Ltd | For profit | 9 | 9 | 3 | 2011 |
| Accelovance | For profit | 4 | 0 | 3 | 2013 |
| INC Research | For profit | 2 | 0 | 1 | 2014 |
| TKL Research | For profit | 2 | 0 | 1 | 2014 |
| AXIS Clinicals Limited | For profit | 1 | 0 | 1 | 2011 |
| Spaulding Clinical Research Inc. | For profit | 1 | 0 | 1 | 2012 |
| Target Health Inc. | For profit | 1 | 0 | 1 | 2013 |
| Universal BioPharma Research Inc. | For profit | 1 | 0 | 1 | 2011 |
Marketing (5)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Dr. Reddy's Laboratories | For profit | MKTG | Jul 24, 2020 |
| Hatchtech Pty Ltd | For profit | MKTG | Jul 24, 2020 |
| Hatchtech Pty Ltd | For profit | NDA2 | Jul 24, 2020 |
| Hatchtech Pty Ltd | For profit | NDA | Jul 24, 2020 |
| Ligand Pharmaceuticals | For profit | MKTG | Jul 24, 2020 |